CriticalReversible MAO-A inhibitor (RIMA)×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, section 5.1). Selegiline inhibits MAO type B irreversibly: the enzyme works again only after new enzyme is made, in platelets after about 2 weeks (selegiline SmPC, section 5.2). Above the recommended dose of 10 mg a day, selegiline may lose its selectivity for MAO-B, and the risk of hypertension rises (selegiline SmPC, section 4.4). When MAO type A in the gut and liver is inhibited, amines from food such as tyramine are absorbed, release noradrenaline and raise blood pressure (selegiline label, US Food and Drug Administration, FDA, section 7.5). According to the selegiline SmPC, selegiline does not cause tyramine-induced hypertension, either alone or with other drugs, except with moclobemide or non-selective MAO inhibitors (section 5.1).
Symptoms
With monoamine oxidase (MAO) inhibitors, selegiline can cause a severe fall or rise in blood pressure and disorders of the central nervous and cardiovascular systems (selegiline summary of product characteristics, SmPC, section 4.5). According to the US Food and Drug Administration (FDA) selegiline label, other MAO inhibitors raise the risk of hypertensive crisis (sections 4 and 7.3). After fermented cheese, herring or over-the-counter cough and cold medicines, blood pressure can rise to the point of uncontrolled hypertension (FDA selegiline label, section 7.5). Selegiline taken with antidepressants has caused serotonin syndrome, including fatal cases, with confusion, agitation, hallucinations, shivering, sweating, high fever, high or low blood pressure, fast heartbeat, muscle rigidity, muscle twitching and tremor (FDA selegiline label, section 5.2).
Management
The combination is contraindicated: selegiline is on the list of drugs contraindicated with moclobemide (moclobemide summary of product characteristics, SmPC, sections 4.3 and 4.5). The selegiline SmPC contraindicates monoamine oxidase (MAO) inhibitors as a group, with linezolid given only as an example (sections 4.3 and 4.5). The moclobemide SmPC classes moclobemide as an MAO type A inhibitor (section 5.1). The US Food and Drug Administration (FDA) selegiline label also contraindicates other MAO inhibitors because of the risk of hypertensive crisis (sections 4 and 7.3). Start moclobemide no earlier than 14 days after stopping selegiline (FDA selegiline label, sections 4 and 7.3). The moclobemide SmPC recommends the same interval when switching from an irreversible MAO inhibitor (section 4.5), and selegiline inhibits MAO irreversibly (selegiline SmPC, section 5.2). No document gives an interval for the opposite switch, from moclobemide to selegiline. If selegiline and an MAO type A inhibitor are nevertheless taken together, the selegiline SmPC recommends limiting foods high in tyramine, such as aged cheese and yeast products (section 4.5). If serotonin syndrome is suspected, consider reducing the moclobemide dose or stopping moclobemide, depending on how severe the symptoms are (moclobemide SmPC, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2